A subsidiary of Sun Pharmaceutical Industries has acquired New England-based firm Pharmalucence, which manufactures human injectable pharmaceuticals. Sun says Pharmalucence has sterile injectable capacity in the U.S., supported by strong R&D capabilities.

Pharmalucence says it provides contract and private label formulation development and manufacturing services of noncytotoxic human injectables in either liquid or lyophilized form. According to the company's website, Pharmalucence has a 70,000 sq. ft. facility it claims to be New England's first CMO to use fully automated and isolated aseptic technology in support of customer needs ranging from small clinical fills to full commercial scale production.

This has been an eventful year for the Indian generics manufacturer as in April Sun Pharma picked up fellow generics firm Ranbaxy Laboratories for $4 billion, with the aim of creating the world’s fifth-largest generic drug company. Also, in May, Sun Pharma closed down its Detroit facility run by Caraco Pharmaceutical Laboratories, of which Sun Pharma is a majority owner. The FDA shut down this facility in 2009 for failing to meet cGMP requirements; the facility reopened in August of 2012.

Previous articleLilly Using Immunocore ImmTAC Technology in Cancer Alliance
Next articleIllumina Buys Myraqa, Continuing Sequencing Push into Clinic